{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:14:10Z","timestamp":1780319650896,"version":"3.54.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"DOI":"10.7759\/cureus.110038","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:58:32Z","timestamp":1780318712000},"source":"Crossref","is-referenced-by-count":0,"title":["Glucagonlike Peptide-1 (GLP-1) Receptor Agonists for Cardiometabolic Risk in Severe Mental Illness: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Catarina","family":"Domingues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Pinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","article-title":"Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care","volume":"10","author":"DE Hert M","year":"2011","unstructured":"DE Hert M, Correll CU, Bobes J, et al.. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011, 10:52-77. 10.1002\/j.2051-5545.2011.tb00014.x","journal-title":"World Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert M","year":"2011","unstructured":"De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011, 8:114-26. 10.1038\/nrendo.2011.156","journal-title":"Nat Rev Endocrinol"},{"key":"ref3","unstructured":"Improving the physical health of people living with severe mental illness (SMI). (2024). Accessed. February 2, 2026: https:\/\/www.england.nhs.uk\/supporting-our-nhs-people\/support-now\/physical-health-and-wellbeing\/."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116645254","article-title":"BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment","volume":"30","author":"Cooper SJ","year":"2016","unstructured":"Cooper SJ, Reynolds GP, Barnes T, et al.. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol. 2016, 30:717-48. 10.1177\/0269881116645254","journal-title":"J Psychopharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger T","year":"2020","unstructured":"Pillinger T, McCutcheon RA, Vano L, et al.. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020, 7:64-77. 10.1016\/S2215-0366(19)30416-X","journal-title":"Lancet Psychiatry"},{"key":"ref6","unstructured":"Bipolar disorder. assessment and management. (2014). Accessed: February 2, 2026: https:\/\/www.nice.org.uk\/guidance\/cg185."},{"key":"ref7","unstructured":"Psychosis and schizophrenia in adults. prevention and management. (2014). Accessed: February 2, 2026: https:\/\/www.nice.org.uk\/guidance\/cg178."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119889296","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology","volume":"34","author":"Barnes TR","year":"2020","unstructured":"Barnes TR, Drake R, Paton C, et al.. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020, 34:3-78. 10.1177\/0269881119889296","journal-title":"J Psychopharmacol"},{"key":"ref9","article-title":"Management of physical health conditions in adults with severe mental disorders: WHO guidelines","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Management of physical health conditions in adults with severe mental disorders: WHO guidelines. World Health Organization, Geneva, Switzerland; 2018."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.2332","article-title":"Semaglutide treatment of antipsychotic-treated patients with schizophrenia, prediabetes, and obesity: the HISTORI randomized clinical trial","volume":"82","author":"Ganeshalingam AA","year":"2025","unstructured":"Ganeshalingam AA, Uhrenholt N, Arnfred S, et al.. Semaglutide treatment of antipsychotic-treated patients with schizophrenia, prediabetes, and obesity: the HISTORI randomized clinical trial. JAMA Psychiatry. 2025, 82:1065-74. 10.1001\/jamapsychiatry.2025.2332","journal-title":"JAMA Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.3639","article-title":"Semaglutide and early-stage metabolic abnormalities in individuals with schizophrenia spectrum disorders: a randomized clinical trial","volume":"83","author":"Sass MR","year":"2026","unstructured":"Sass MR, Klausen MK, Schwarz CR, et al.. Semaglutide and early-stage metabolic abnormalities in individuals with schizophrenia spectrum disorders: a randomized clinical trial. JAMA Psychiatry. 2026, 83:128-38. 10.1001\/jamapsychiatry.2025.3639","journal-title":"JAMA Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial","volume":"74","author":"Larsen JR","year":"2017","unstructured":"Larsen JR, Vedtofte L, Jakobsen MS, et al.. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry. 2017, 74:719-28. 10.1001\/jamapsychiatry.2017.1220","journal-title":"JAMA Psychiatry"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12982","article-title":"One-year follow-up on liraglutide treatment for prediabetes and overweight\/obesity in clozapine- or olanzapine-treated patients","volume":"139","author":"Svensson CK","year":"2019","unstructured":"Svensson CK, Larsen JR, Vedtofte L, et al.. One-year follow-up on liraglutide treatment for prediabetes and overweight\/obesity in clozapine- or olanzapine-treated patients. Acta Psychiatr Scand. 2019, 139:26-36. 10.1111\/acps.12982","journal-title":"Acta Psychiatr Scand"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.113670","article-title":"Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes-randomized controlled trial","volume":"296","author":"Maagensen H","year":"2021","unstructured":"Maagensen H, Larsen JR, J\u00f8rgensen NR, Fink-Jensen A, Vilsb\u00f8ll T. Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes-randomized controlled trial. Psychiatry Res. 2021, 296:113670. 10.1016\/j.psychres.2020.113670","journal-title":"Psychiatry Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12795","article-title":"Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial","volume":"19","author":"Ish\u00f8y PL","year":"2017","unstructured":"Ish\u00f8y PL, Knop FK, Broberg BV, et al.. Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2017, 19:162-71. 10.1111\/dom.12795","journal-title":"Diabetes Obes Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13522","article-title":"Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis","volume":"21","author":"Siskind D","year":"2019","unstructured":"Siskind D, Hahn M, Correll CU, et al.. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis. Diabetes Obes Metab. 2019, 21:293-302. 10.1111\/dom.13522","journal-title":"Diabetes Obes Metab"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2022.07.006","article-title":"A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis","volume":"78","author":"Lee K","year":"2022","unstructured":"Lee K, Abraham S, Cleaver R. A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. Gen Hosp Psychiatry. 2022, 78:58-67. 10.1016\/j.genhosppsych.2022.07.006","journal-title":"Gen Hosp Psychiatry"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2024.06.003","article-title":"Pharmacological interventions for antipsychotic-induced weight gain in schizophrenia: a network meta-analysis","volume":"90","author":"Hegde NC","year":"2024","unstructured":"Hegde NC, Mishra A, Maiti R, Mishra BR, Mohapatra D, Srinivasan A. Pharmacological interventions for antipsychotic-induced weight gain in schizophrenia: a network meta-analysis. Gen Hosp Psychiatry. 2024, 90:12-21. 10.1016\/j.genhosppsych.2024.06.003","journal-title":"Gen Hosp Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/483018-glucagonlike-peptide-1-glp-1-receptor-agonists-for-cardiometabolic-risk-in-severe-mental-illness-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:58:33Z","timestamp":1780318713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/483018-glucagonlike-peptide-1-glp-1-receptor-agonists-for-cardiometabolic-risk-in-severe-mental-illness-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.110038","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}